A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

NCT07018544 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

840

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity and Overweight

Interventions

OTHER: semaglutide

Sponsor

Novo Nordisk A/S